A Phase 2 interventional study of ISL and LEN in HIV-1 Infection, sponsored by Gilead Sciences. Active, not recruiting at 44 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologically suppressed people with HIV (PWH) at Week 24.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Any of the following laboratory values at screening:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the following for at least 48 weeks: * Day 1 and Day 2: ISL 40 and LEN 600 mg * Day 8 and weekly thereafter (ie, every 7 days): ISL 20 mg and LEN 300 mg
Drug: ISL · Drug: LEN
Participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg once daily for at least 48 weeks After 48 weeks, participants will switch from B/F/TAF to ISL+LEN * ISL 40 and LEN 600 mg on Day 1 and Day 2 * ISL 20 mg and LEN 300 mg weekly Participants who do not switch from B/F/TAF to ISL+LEN at Week 48 will be discontinued from the study.
Drug: ISL · Drug: LEN · Drug: B/F/TAF
Participants will receive the following for at least 48 weeks * Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg) * Day 2: LEN only oral 600 mg (2 x 300 mg) * Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg
Drug: ISL · Drug: LEN
Participants will receive B/F/TAF 50/200/25 mg once daily for at least 48 weeks.
Drug: ISL · Drug: LEN · Drug: B/F/TAF
After 48 Weeks of randomized treatment, all participants will be given an option to participate in an Extension Phase to receive ISL+LEN or ISL/LEN FDC tablet (when available) until ISL/LEN becomes available or until the sponsor elects to discontinue the study, whichever occurs first. Participants receiving ISL+LEN during the randomized phase will continue to take ISL + LEN weekly. Participants receiving B/F/TAF during the randomized phase will switch to ISL+LEN: * Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg) * Day 2: LEN only oral 600 mg (2 x 300 mg) * Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg Participants who do not switch from B/F/TAF to ISL+LEN at Week 48 will be discontinued from the study. All participants in the extension phase will be transitioned to weekly ISL/LEN FDC (Dose A) tablet when it becomes available.
Drug: ISL/LEN FDC
Capsules administered orally without regard to food
Tablets administered orally without regard to food
Also known as: GS-6207
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
Tablets administered orally without regard to food
Also known as: Biktarvy®
Tablets administered orally without regard to food
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 24 window was between Day 148 and 189 (inclusive). Percentages were rounded off.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 12 window was between Day 71 and 105 (inclusive). Percentages were rounded off.
Time frame: Week 12
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 48 window was between Day 316 and 378 (inclusive). Percentages were rounded off.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 12 window was between Day 71 and 105 (inclusive). Percentages were rounded off.
Time frame: Week 12
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 24 window was between Day 148 and 189 (inclusive). Percentages were rounded off.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 48 window was between Day 316 and 378 (inclusive). Percentages were rounded off.
Time frame: Week 48
Change From Baseline in Clusters of Differentiation 4 (CD4)+ Cell Count at Week 12
Time frame: Baseline and Week 12
Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline and Week 24
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline and Week 48
Percentage of Participants Experiencing Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation
TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.
Time frame: Up to 5 years
Cohort 1: Plasma Concentrations for ISL
Time frame: Anytime postdose at Week 4
Cohort 2: Pharmacokinetic (PK) Parameter: Cmax of Islatravir (ISL)
Cmax was defined as the maximum observed concentration of drug.
Time frame: Anytime post dose on Day 1 and at either Week 12 or Week 18
Cohort 2: PK Parameter: Tmax of ISL
Tmax was defined as the time (observed time point) of Cmax.
Time frame: Anytime post dose on Day 1 and at either Week 12 or Week 18
Cohort 2: PK Parameter: Ctau of ISL
Ctau was defined as the observed drug concentration at the end of the dosing interval.
Time frame: Anytime post dose at either Week 12 or Week 18
Cohort 2: PK Parameter: AUCtau of ISL
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: Anytime post dose at either Week 12 or Week 18
Plasma Concentrations for LEN
Time frame: Anytime postdose at Week 4
Cohort 2: Pharmacokinetic (PK) Parameter: Cmax of LEN
Cmax was defined as the maximum observed concentration of drug.
Time frame: Anytime post dose on Day 1, Day 2 and at either Week 12 or 18
Cohort 2: PK Parameter: Tmax of LEN
Tmax is defined as the time (observed time point) of Cmax.
Time frame: Anytime post dose on Day 1, Day 2 and at either Week 12 or Week 18
Cohort 2: PK Parameter: Ctau of LEN
Ctau was defined as the observed drug concentration at the end of the dosing interval.
Time frame: Anytime post dose at either Week 12 or Week 18
Cohort 2: PK Parameter: AUCtau of LEN
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: Anytime post dose at either Week 12 or Week 18
Participants were enrolled at study sites in the United States. This is the primary results analysis including data up to Week 48 for the outcome measures. As Cohort 1 never reached Week 48, so, the data for some outcome measures for applicable timepoints up to Week 48 were reported for Cohort 2 only.
| Milestone | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Started | 24 | 12 | 53 | 53 |
| Completed | 0 | 0 | 2 | 4 |
| Not completed | 24 | 12 | 51 | 49 |
| Withdrew: Still on study | 0 | 0 | 47 | 44 |
| Withdrew: Cohort terminated by sponsor | 21 | 12 | 0 | 0 |
| Withdrew: Withdrew consent | 1 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
| Withdrew: Randomized but never treated | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 24 window was between Day 148 and 189 (inclusive). Percentages were rounded off.
| percentage of participants | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm | — | — | 1.9 | 0 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 12 window was between Day 71 and 105 (inclusive). Percentages were rounded off.
| percentage of participants | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm | — | — | 1.9 | 0 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 48 window was between Day 316 and 378 (inclusive). Percentages were rounded off.
| percentage of participants | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm | — | — | 0 | 0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 12 window was between Day 71 and 105 (inclusive). Percentages were rounded off.
| percentage of participants | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm | — | — | 98.1 (89.7 to 100) | 96.2 (86.8 to 99.5) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 24 window was between Day 148 and 189 (inclusive). Percentages were rounded off.
| percentage of participants | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm | — | — | 94.2 (84.1 to 98.8) | 96.2 (86.8 to 99.5) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 48 window was between Day 316 and 378 (inclusive). Percentages were rounded off.
| percentage of participants | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm | — | — | 96.2 (86.8 to 99.5) | 94.2 (84.1 to 98.8) |
| cells/µL | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Baseline | 721 ± 265.0 | 659 ± 304.8 | 755 ± 223.6 | 818 ± 271.3 |
| Change at Week 12 | -50 ± 183.0 | 18 ± 142.3 | -23 ± 185.6 | -49 ± 180.0 |
| cells/µL | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 24 | — | — | -4 ± 182.1 | -57 ± 204.2 |
| cells/µL | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | — | — | -12 ± 214.7 | -29 ± 186.1 |
TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.
Results for this outcome have not been posted.
| ng/mL | Cohort 1- Group 1 (ISL+LEN) |
|---|---|
| Cohort 1: Plasma Concentrations for ISL | 42.1 ± 49.6 |
Cmax was defined as the maximum observed concentration of drug.
| ng/mL | Cohort 2- Group 1 (ISL+LEN) |
|---|---|
| Day 1 | 19.6 ± 6.55 |
| Week 12 or Week 18 | 18.7 ± 7.6 |
Tmax was defined as the time (observed time point) of Cmax.
| hours | Cohort 2- Group 1 (ISL+LEN) |
|---|---|
| Day 1 | 1.12 ± 1.03 |
| Week 12 or Week 18 | 0.793 ± 0.423 |
Ctau was defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | Cohort 2- Group 1 (ISL+LEN) |
|---|---|
| Cohort 2: PK Parameter: Ctau of ISL | 0.169 ± 0.0940 |
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| h*ng/mL | Cohort 2- Group 1 (ISL+LEN) |
|---|---|
| Cohort 2: PK Parameter: AUCtau of ISL | 132 ± 98.1 |
| ng/mL | Cohort 1- Group 1 (ISL+LEN) |
|---|---|
| Plasma Concentrations for LEN | 62.0 ± 43.9 |
Cmax was defined as the maximum observed concentration of drug.
| ng/mL | Cohort 2- Group 1 (ISL+LEN) |
|---|---|
| Day 1 | 46.4 ± 29.0 |
| Day 2 | 183 ± 189 |
| Week 12 or Week 18 | 97.4 ± 73.2 |
Tmax is defined as the time (observed time point) of Cmax.
| hours | Cohort 2- Group 1 (ISL+LEN) |
|---|---|
| Day 1 | 11.4 ± 8.96 |
| Day 2 | 6.61 ± 1.47 |
| Week 12 or Week 18 | 5.43 ± 1.63 |
Ctau was defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | Cohort 2- Group 1 (ISL+LEN) |
|---|---|
| Cohort 2: PK Parameter: Ctau of LEN | 36.6 ± 22.5 |
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| h*ng/mL | Cohort 2- Group 1 (ISL+LEN) |
|---|---|
| Cohort 2: PK Parameter: AUCtau of LEN | 10000 ± 7440 |
Collected over All-Cause Mortality: Cohort 1: Up to Week 12; Cohort 2: Up to Week 74.6. Adverse Events: Cohort 1: Up to Week 12; Cohort 2: Up to Week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1- Group 1 (ISL+LEN) | 0/24 (0%) | 0/24 (0%) | 11/24 (45.8%) |
| Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Cohort 2- Group 1 (ISL+LEN) | 0/53 (0%) | 3/52 (5.8%) | 27/52 (51.9%) |
| Cohort2- Group 2 (B/F/TAF to ISL+LEN) | 0/53 (0%) | 0/52 (0%) | 29/52 (55.8%) |
| Event | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Large intestine perforationGastrointestinal disorders | 0/24 | 0/12 | 1/52 | 0/52 |
| PneumoniaInfections and infestations | 0/24 | 0/12 | 1/52 | 0/52 |
| Anaesthetic complication neurologicalInjury, poisoning and procedural complications | 0/24 | 0/12 | 1/52 | 0/52 |
| Renal colicRenal and urinary disorders | 0/24 | 0/12 | 1/52 | 0/52 |
| Event | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) |
|---|---|---|---|---|
| Covid-19Infections and infestations | 7/24 | 2/12 | 6/52 | 6/52 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/24 | 2/12 | 3/52 | 3/52 |
| Upper respiratory tract infectionInfections and infestations | 1/24 | 0/12 | 7/52 | 7/52 |
| DiarrhoeaGastrointestinal disorders | 0/24 | 0/12 | 6/52 | 3/52 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/24 | 0/12 | 3/52 | 5/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/24 | 0/12 | 0/52 | 5/52 |
| NauseaGastrointestinal disorders | 2/24 | 0/12 | 3/52 | 1/52 |
| FolliculitisInfections and infestations | 1/24 | 1/12 | 2/52 | 0/52 |
| SinusitisInfections and infestations | 1/24 | 1/12 | 1/52 | 1/52 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/24 | 1/12 | 0/52 | 0/52 |
Safety analysis set included all participants who received at least 1 dose of study drugs.
| Age, Categorical(Participants) | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 22 | 12 | 50 | 46 | 130 |
| >=65 years | 2 | 0 | 2 | 6 | 10 |
| Age, Continuous(years) | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) | Total |
|---|---|---|---|---|---|
| Mean | 42 ± 11.9 | 40 ± 11.2 | 43 ± 12.1 | 45 ± 13.3 | 43 ± 12.4 |
| Sex: Female, Male(Participants) | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) | Total |
|---|---|---|---|---|---|
| Female | 2 | 1 | 10 | 9 | 22 |
| Male | 22 | 11 | 42 | 43 | 118 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 4 | 13 | 17 | 41 |
| Not Hispanic or Latino | 17 | 8 | 39 | 35 | 99 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) | Total |
|---|---|---|---|---|---|
| White | 10 | 6 | 25 | 27 | 68 |
| Black or African American | 13 | 5 | 21 | 16 | 55 |
| Other or More Than One Race | 1 | 0 | 3 | 5 | 9 |
| Asian | 0 | 1 | 2 | 1 | 4 |
| American Indian or Alaska Native | 0 | 0 | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Cohort 1- Group 1 (ISL+LEN) | Cohort 1- Group 2 (B/F/TAF to ISL+LEN) | Cohort 2- Group 1 (ISL+LEN) | Cohort2- Group 2 (B/F/TAF to ISL+LEN) | Total |
|---|---|---|---|---|---|
| United States | 24 | 12 | 52 | 52 | 140 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Dec 2023, 26 months.
Results were first posted in Jan 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Islatravir · Lenacapavir